Keying Xu

Keying Xu

Auto-generated profile, based on publicly available information

Keying Xu

Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Purpose: Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. Experimental Design: 3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates. Results: For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively. Conclusions: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.

1 November 2020 in International Journal of Surgery
Verified
Journal Article
Closed access
CGChristopher D. Griffiths
Christopher D. Griffiths
KXKeying Xu
Keying Xu
JWJulian Wang
Julian Wang
TMTyler McKechnie
Tyler McKechnie
AGAmiram Gafni
Amiram Gafni
Pablo Emilio SerranoPablo Emilio Serrano
Pablo Emilio Serrano
Laparoscopic hepatectomy (LH) has been deemed safe, and, in the case of minor hepatectomy, the standard of care. Short-, long-term outcomes and costs of LH compared with open hepatectomy (OH) in patients with colorectal cancer liver metastases have not been well described at the population level. Patients diagnosed with colorectal cancer undergoing hepatectomy were included in this population-based retrospective cohort study from 2006- to 2014. Postoperative complications (per Clavien-Dindo) and survival were analyzed using a linear mixed model and Cox-Proportional hazards model respectively. Costs of surgery and the 90-day postoperative period were considered in 2018 Canadian dollars and compared from the perspective of a third-party payer. Over a median follow-up of 56 months, 95% confidence interval (CI): 51 to 68), there were 2991 hepatectomies (OH: 2551 (85%) and LH: 440 (15%)). LH compared to OH was more common for patients >70 years-old (30% vs. 22%, p = 0.004) and for minor hepatectomy (52% vs. 32%, p < 0.001) respectively. By multivariable analyses, OH was associated with similar 90-day mortality (Odds Ratio (OR) 1.05, 95% CI: 0.56-1.97), and overall survival (Hazard Ratio (HR) 1.08, 95% CI: 0.90-1.29), but higher rates of major postoperative complications (OR 1.34, 95% CI: 1.03-1.76), higher cost (median difference $6,163, 95% CI: $3229 to $9096), and longer length of hospital stay (LOS) (mean difference 3.04 days, 95% CI: 2.7 to 3.91). LH was associated with lower postoperative complications, shorter LOS, which translated into lower costs to the healthcare system, without differences in postoperative mortality and survival.

1 January 2020 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
Junwei ShiJunwei Shi
Junwei Shi
BGBlaine Granger
Blaine Granger
KXKeying Xu
Keying Xu
YYYidong Yang
Yidong Yang
Background: This work proposed a joint L1 and total variation (TV) regularized reconstruction method for X-ray fluorescence tomography (XFT), and investigated the performance of this method in quantitative imaging of gold nanoparticles (GNPs). Methods: We developed a dual-modality XFT/CT imaging system which consisted of a benchtop X-ray source, a translation/rotation stage, a silicon drift detector for X-ray fluorescence (XRF) detection, and a flat panel detector for transmission X-ray detection. A pencil-beam collimator was 3D printed with steel and employed in sample excitation. The sensitivity of the XFT imaging system was determined by imaging water phantoms with multiple inserts containing GNP solutions of various concentrations (0.02–0.16 wt.%). A joint L1 and total variation (TV) regularized algorithm was developed for XFT reconstruction, where the L1 regularization was used to reduce image artifacts and the TV regularization was used to preserve the shape of targets. Nonlinear conjugate gradient (NCG) descent algorithm with backtracking line search was adopted to solve the reconstruction problem. We compared the L1 + TV regularization method with filtered back projection (FBP), maximum likelihood expectation maximization (ML-EM), L1 regularization, and TV regularization methods. Contrast-to-noise ratio (CNR), Dice similarity coefficient (DSC) and localization error (LE) metrics were used to compare the performance of different methods. The CT and XFT imaging doses were also measured using EBT2 radiochromic films. Results: The 3D printed pencil-beam collimator shaped an excitation beam with a 2 mm full width at half maximum at the imaging isocenter. Based on the phantom imaging experiments, the joint L1 and TV regularization method performed better than FBP, ML-EM, L1 regularization and TV regularization methods, with higher localization accuracy (offset 0.99) between the reconstructed and true GNP concentration. The estimated XFT imaging dose is about 41.22 cGy under current setting. Conclusions: The joint L1 + TV regularized reconstruction algorithm performed better in noise suppression and shape preservation. Using the L1 + TV regularized reconstruction, the XFT system is able to localize GNP targets with submillimeter accuracy and quantify GNP distribution at a concentration of 0.02 wt.% or lower.

15 April 2024
Verified
Other
Open access
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).

15 April 2024
Verified
Other
Open access
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).

15 April 2024
Verified
Other
Open access
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.